Inefficient ubiquitination of AD patients will cause the decreased parkin-beclin-1 interaction, while nilotinib could improve the levels of endogenous parkin by inhibiting the tyrosine-phosphorylation of parkin, thereby promoting the self-ubiquitination and Aβ clearance [74, 75]. The gene discussed is PRKN; the disease is Alzheimer disease.